Preparation and characterization of solid lipid nanoparticles containing cyclosporine by the emulsification-diffusion method

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 611-620

  Urbán Morlán, Zaida ^a   Ganem Rondero, Adriana ^a   Melgoza Contreras, Luz María ^b   Escobar Chávez, José Juan ^a,b   Nava Arzaluz, María Guadalupe ^a   Quintanar Guerrero, David ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

Author keywords

Cyclosporine; Dispersion stability; Emulsification diffusion method; Glyceryl behenate; Lauroyl macrogolglycerides; Solid lipid nanoparticles

Indexed keywords

ACYLGLYCEROL; CYCLOSPORIN; DRUG CARRIER; GLYCEROL BEHENATE; SOLID LIPID NANOPARTICLE; EMULSIFYING AGENT; FATTY ACID; GELUCIRE 44 14; GELUCIRE 44-14; LIPID; MACROGOL DERIVATIVE; NANOPARTICLE;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; IN VITRO STUDY; LIPID ANALYSIS; NANOANALYSIS; NANOEMULSION; NANOFABRICATION; PARTICLE SIZE; ROOM TEMPERATURE; SCANNING ELECTRON MICROSCOPY; ZETA POTENTIAL; CHEMISTRY; DIFFUSION; NANOMEDICINE; THERMODYNAMICS; ULTRASTRUCTURE;

CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; DIFFUSION; DRUG CARRIERS; DRUG STABILITY; EMULSIFYING AGENTS; FATTY ACIDS; LIPIDS; MICROSCOPY, ELECTRON, SCANNING; NANOMEDICINE; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; THERMODYNAMICS;

EID: 79952115422     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S12125     Document Type: Article

References (35)

1. Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242(1-2): 121-128.
2. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J Biotech. 2004;113(1-3):151-170.
3. Trotta M, Cavalli R, Trotta C, Bussano R, Costa L. Electrospray technique for solid lipid-based particle production. Drug Dev Ind Pharm. 2010;36(4):431-438.
4. Battaglia L, Gallarate M, Cavalli R, Trotta M. Solid lipid nanoparticles produced through a coacervation method. J Microencaps. 2010;27(1): 78-85.
5. Singh S, Dobhal AK, Jain A, Pandit JK, Chakraborty S. Formulation and evaluation of solid lipid nanoparticles of a water soluble drug: zidovidine. Chem Pharm Bull. 2010;58(5):650-655.
6. del Pozo-Rodríguez A, Delgado D, Solinis MA, et al. Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration. Int J Pharm. 2010;385(1-2): 157-162.
7. Varshosaz J, Minayian M, Moazen E. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J Liposome Research. 2010;20(2):115-123.
8. Hu L, Jia H, Luo Z, Liu C, Xing Q. Improvement of digoxin oral absorption in rabbits by incorporation into solid lipid nanoparticles. Pharmazie. 2010;65(2):110-113.
9. Mehnert W, Mader K. Solid lipid nanoparticles. Production, characterization, and applications. Adv Drug Deliv Rev. 2001;47(2-3):165-196.
10. Quintanar-Guerrero D, Tamayo-Esquivel D, Ganem-Quintanar A, Allémann E, Doelker E. Adaptation and optimization of the emulsificationdiffusion technique to prepare lipidic nanospheres. Eur J Pharm Sci. 2005;26(2):211-218.
11. Tamayo-Esquivel D, Ganem-Quintanar A, Martinez AL, Navarrete- Rodriguez M, Rodriguez-Romo S, Quintanar-Guerrero D. Evaluation of the enhanced oral effect of omapatrilat-monolein nanoparticles prepared by the emulsification-diffusion method. J Nanosci Nanotechnol. 2006;6(9-10):3134-3138.
12. Yi Fan L, Da Wei C, Li Xiang R, Xiu Li Z, Jing Q. Solid lipid nanoparticles for enhancing vinpocetinés oral bioavailability. J Control Release. 2006;114(1):53-59.
13. Nan Z, Qineng P, Guihua H, Wenfang X, Yanna Ch, Xiuzhen H. Lectinmodified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm. 2006;327(1-2):153-159.
14. Kovarik JM, Mueller EA, van Bree JB, Tetzloff W, Kutz K. Reduced inter- and intra-individual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci. 1994;83(3): 444-446.
15. Molpeceres J, Guzman M, Aberturas MR, Chacon M, Berges L. Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement. J Pharm Sci. 1996;85(2):206-213.
16. Tarr BD, Yalkowsky SH. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm Res. 1989;6(1):40-43.
17. Sanchez A, Vila-Jato JL, Alonso MJ. Development of biodegradable microspheres and nanospheres for the controlled release of cyclosporine A. Int J Pharm. 1993;99(2-3):263-273.
18. Guzman M, Molpeceres J, Garcia F, Aberturas MR, Rodriguez M. Formation and characterization of cyclosporine-loaded nanoparticles. J Pharm Sci. 1993;82(5):498-502.
19. Al-Angary AA, Bayomi MA, Khidr SH, Al-Meshal MA, Al-Dardiri M. Characterization, stability, and in vivo targeting of liposomal formulations containing cyclosporin. Int J Pharm. 1995; 114(2):221-225.
20. ®) versus drug nanocrystals. Int J Pharm. 2006;317(1):82-89.
21. ®): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm. 2008;68(3):535-544.
22. Varia JK, Dodiya SS, Sawant KK. Cyclosporine A loaded solid lipid nanoparticles: optimization of formulation, process variable, and characterization. Curr Drug Del. 2008;5(1):64-69.
23. Gokce EH, Sandri G, Bonferoni MC, et al. Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm. 2008;364(1):76-86.
24. Hanafy A, Spahn-Langguth H, Vergnault G, et al. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev. 2007;59(6):419-426.
25. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution, and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release. 2005;107(2): 215-228.
26. Tamayo-Esquivel D. (2005). Preparación de dispersiones lipídicas de talla submicrónica por medio del método de emulsificación difusión, Tesis de Maestría, Universidad Nacional Autónoma de México.
27. Allemann E, Doelker E, Gurny R. Drug loaded poly(lactic acid) nanoparticles produced by a reversible salting-out process, purification of an injectable dosage form. Eur J Pharm Biopharm. 1993;39(1):13-18.
28. Quintanar-Guerrero D, Allemann E, Doelker E, Fessi H. A mechanistic study of the formation of polymer nanoparticles by the emulsiondiffusion technique. Colloid Polym Sci. 1997;275(7):640-647.
29. Pinon-Segundo E, Ganem-Quintanar A, Alonso-Perez V, Quintanar-Guerrero D. Preparation and characterization of triclosan nanoparticles for periodontal treatment. Int J Pharm. 2005;294(1-2):217-232.
30. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
31. Westesen K, Bunjes H, Koch MHJ. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release. 1997;48(2-3): 223-236.
32. Heurtault B, Saulnier P, Pech B, Prust JE, Benoit JP. Physicochemical stability of colloidal lipid particles. Biomaterials. 2003;24(23): 4283-4300.
33. Lechuga-Ballesteros D, Abdul-Fattah A, Stevenson CL, Bennett DB. Properties and stability of a liquid crystal form of Cyclosporine - the first reported naturally occurring peptide that exists as a thermotropic liquid crystal. J Pharm Sci. 2003;92(9):1821-1831.
34. Grasso D, Milardi D, La Rosa C, Impellizzeri G, Pappalardo G. The interaction of a peptide with a scrambled hydrophobic/hydrophilic sequence (Pro-Asp-Ala-Asp-Ala-His-Ala-His-Ala-His-Ala-Ala- Ala-His-Gly) (PADH) with DPPC model membranes: a DSC study. Thermochim Acta. 2002;390(1-2):73-78.
35. Panicker L. Influence of the leprosy drug, dapsone, on the model membrane dipalmitoyl phosphatidylethanolamine. Thermochim Acta. 2006;447(2):123-130.